Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus plantarum TCI378
- Development stage
- Unknown
- Lead developer
- TCI
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum TCI378 is a probiotic bacterial strain isolated from naturally fermented Korean kimchi. Developed by TCI using advanced bioresource data mining, it is marketed as ProbioFit and has demonstrated clinically supported benefits for weight management and fat reduction. The primary mechanism involves high bile salt hydrolase (BSH) activity, which breaks down bile salts in the gut, thereby disrupting fat emulsification and absorption. This leads to reduced dietary fat storage and increased excretion of fats. In vitro studies show that both live bacteria and their metabolites suppress adipocyte-specific genes such as perilipin 1 and glucose transporter type 4 (GLUT4), further supporting anti-obesity effects. Clinical trials have shown efficacy in reducing body weight without medication or dietary restrictions[1][2][3][6][8].
- Brand names
- ProbioFit
- Other names
- Lactobacillus plantarum TCI378ProbioFit
02
Targets
BSH (Bile salt hydrolase)
Beyond the preview
Go deeper on Lactobacillus plantarum TCI378.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus plantarum TCI378.